CDXS logo

Codexis Inc. (CDXS)

$1.07

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CDXS

Market cap

$117269356

EPS

-0.18

P/E ratio

--

Price to sales

1.99

Dividend yield

--

Beta

2.383428

Price on CDXS

Previous close

$1.06

Today's open

$1.07

Day's range

$1.04 - $1.12

52 week range

$0.90 - $2.98

Profile about CDXS

CEO

Alison Moore

Employees

146

Headquarters

Redwood City, CA

Exchange

Nasdaq Global Select

Shares outstanding

109597529

Issue type

Common Stock

CDXS industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CDXS

What Codexis (CDXS) Said on Its Q3 Earnings Call

Codexis NASDAQ: CDXS reported higher third-quarter revenue and a narrower loss as its pharmaceutical biocatalysis business grew, while executives outlined progress toward commercial adoption of the company's ECO Synthesis platform for manufacturing oligonucleotide medicines.

news source

MarketBeat • Nov 13, 2026

news preview

Codexis, Inc. (CDXS) Q3 2026 Earnings Call Transcript

Codexis, Inc. (CDXS) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 13, 2026

news preview

Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update

Reports revenue of $19.3 million for the third quarter of 2026, company reiterates full-year revenue guidance Shared new advances in RNA therapeutic manufacturing at TIDES Europe Entered into a $60 million term loan facility with Trinity Capital; initial tranche used to refinance current debt REDWOOD CITY, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

news source

GlobeNewsWire • Nov 12, 2026

news preview

Codexis (CDXS) Reports Q3 Loss, Beats Revenue Estimates

Codexis (CDXS) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.22 per share a year ago.

news source

Zacks Investment Research • Nov 13, 2026

news preview

Codexis Enters into $60 Million Term Loan Facility with Trinity Capital

REDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into a $60 million senior secured term loan agreement with Trinity Capital Inc. (NYSE: TRIN), a leading provider of flexible capital solutions for life sciences and healthcare industries.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities

Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results showcasing that stereochemical control relates to biological efficacy Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results showcasing that stereochemical control relates to biological efficacy

news source

GlobeNewsWire • Nov 9, 2026

news preview

Codexis to Report Third Quarter 2026 Financial Results on November 12

REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2026 on Thursday, November 12, 2026, following the close of market.

news source

GlobeNewsWire • Oct 29, 2026

news preview

Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform.

news source

GlobeNewsWire • Sep 28, 2026

news preview

Codexis to Participate in Cantor Global Healthcare Conference 2026

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York.

news source

GlobeNewsWire • Aug 27, 2026

news preview

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

news source

Zacks Investment Research • Aug 14, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Codexis Inc.

Open an M1 investment account to buy and sell Codexis Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CDXS on M1